These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10085698)

  • 1. [Short-term intensive insulin therapy as a method of overcoming secondary failure of sulfonylureas in patients with type 2 diabetes (non-insulin-dependent)].
    Jedynasty K; Kasperska-Czyzykowa T; Stepień K; Nowaczyk R
    Pol Arch Med Wewn; 1998 Jun; 99(6):442-51. PubMed ID: 10085698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
    Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
    Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD; Balfour JA
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM; Kabadi MU
    J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Personal experience with combined treatment of gliclazide and insulin in patients with non-insulin-dependent diabetes (type 2) and late secondary failure of sulphonylureas].
    Zapecka-Dubno B; Wiśniewska K; Szczepanik Z; Kasperska-Czyzykowa T
    Pol Arch Med Wewn; 1993 Jun; 89(6):499-506. PubMed ID: 8415212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Maifreni L; Duner E; Lisato G; Iavicoli M; Tiengo A
    Diabetologia; 1990 Nov; 33(11):688-95. PubMed ID: 2127573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
    Olsson PO; Lindström T
    Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.
    Galic E; Vrtovec M; Bozikov V; Schwarzenhofer M; Milicevic Z
    Med Sci Monit; 2005 Dec; 11(12):PI87-92. PubMed ID: 16319804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes.
    Choudhary P; Lonnen K; Emery CJ; MacDonald IA; MacLeod KM; Amiel SA; Heller SR
    Diabet Med; 2009 Jul; 26(7):665-72. PubMed ID: 19573114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
    Ehlers MR; Klaff LJ; D'Alessio DA; Brazg R; Kay HD; Harley RE; Mathisen AL; Schneider R
    Horm Metab Res; 2003 Oct; 35(10):611-6. PubMed ID: 14605997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA; Zinman B; Campos RV; Strack T;
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
    Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
    Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team.
    Landstedt-Hallin L; Arner P; Lins PE; Bolinder J; Olsen H; Groop L
    Diabet Med; 1999 Oct; 16(10):827-34. PubMed ID: 10547209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.